pediatric participants (from birth to <18 years) undergoing contrast-enhanced MRI
Conditions
Interventions
- Drug: Gadoquatrane (BAY1747846)
0.04 mmol Gd/kg body weight, solution for intravenous injection, single dose
Sponsors
Myoishi Masafumi
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: - Participants from birth to <18 years of age at the time of signing the informed consent form. - Participants who have a clinical indication to undergo a CE-MRI for any clinical condition in any body region and who can undergo study procedures as per Investigator judgement. - Participants can be male or female (according to their reproductive organs and functions assigned by chromosomal complement). - Female contraception and barriers as well as pregnancy testing is required as appropriate for the age and sexual activity of pediatric participants and as required by local regulations. - The legal guardian(s) is capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. - When applicable by law for a participant, a legal guardian must be available to help the study-site personnel ensure follow up, accompany the participant to the study site on each assessment day, and consistently and consecutively be available to provide information on the participant during the scheduled study visits.
Exclusion criteria
Exclusion criteria: - Body weight <2500 g at screening and baseline - The medical condition and/or local allowance for maximum blood draw in the pediatric participant is not suitable for study procedures, including pharmacokinetics (PK) and safety blood draws, without compromising any expected clinical care/procedure need. - Acute kidney injury (i.e., acute renal failure). - Age-adjusted renal function is decreased (eGFR <80% of age adjusted normal renal function) as evaluated by the investigator based on a serum creatinine result obtained within 2 weeks prior to study intervention. - Considered clinically unstable or has a concurrent/concomitant condition that may not allow participation for the full planned study period, in the judgement of the investigator. - History of moderate to severe allergic-like reaction to any GBCA. - Bronchial asthma considered unstable or had major therapeutical modification within last 4 weeks. - Severe cardiovascular disease, except for cardiac or vascular magnetic resonance (MR), if considered clinically justified by the investigator. - Planned or expected intervention (e.g., treatment or procedure) or change in treatment (e.g. start of chemotherapy) that may significantly affect study parameters (i.e. safety/adverse events [AEs] [e.g. confounding AEs or safety events due to surgery or chemotherapy], PK parameters) or would prevent the participant from performing study procedures, from the administration of gadoquatrane up to the 24 h +- 4 h follow-up. - Participants who received or will receive any other contrast agent within 72 hours prior to gadoquatrane injection or up to 72 hours after gadoquatrane injection. - Contraindications to the administration of GBCAs (depending on local product label), or history of adverse reaction to GBCAs.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Area under the curve (AUC) of gadoquatrane after single administration 2. Plasma clearance normalized to body weight (CL/BW) of gadoquatrane after single administration 3. Apparent volume of distribution at steady state normalized to body weight (Vss/BW) of BAY1747846 after single administration 4. Simulation of plasma concentration at 20 min post-injection (C20) | — |
Countries
Argentina, Belgium, Bulgaria, Canada, China, Czechia, Germany, Hungary, Japan, Poland, Sweden, United States
Contacts
Public Contactcontact Dedicated
Bayer Yakuhin, Ltd.
Outcome results
None listed